Arthelbert Louis Parker
Known title: DirectorCIK: 0001852097
Associated companies
Transaction History
| BCO | ▲ Buy | Option Exercise | 1,844 | $0 | 4/28/2026 | View on chart |
| BCO | ▼ Sell | Open Market | 540 | $62K | 8/14/2025 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,705 | — | 5/2/2025 | View on chart |
| BCO | ▲ Buy | Option Exercise | 2,402 | — | 5/2/2024 | View on chart |
| BCO | ▼ Sell | Open Market | 1,650 | $122K | 8/24/2023 | View on chart |
| BCO | ▲ Buy | Option Exercise | 2,652 | — | 5/5/2023 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,818 | — | 5/6/2022 | View on chart |
| BCO | ▲ Buy | Option Exercise | 216 | $0 | 3/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.